Article Figures & Data
Figures
- FIG 1.
Stump condition: tapered stump (A), blunt stump (B), no stump (C)
- FIG 2.
An adult man who presented with blurred vision for 1 month and right-limb weakness for 10 days. On DSA, the occluded segment is from C1 (B) to C6 (A). On VWI, 3D T1-weighted turbo spin-echo sequences show that the occluded segment is C1 (arrow) to C6 (arrow) (C). The signal intensity of the distal segment in a elliptical region-of-interest (ROI) (D), and the signal intensity of the origin segment is heterogeneous intensity in a elliptical ROI (E).
- FIG 3.
An adult woman who presented with dizziness for 2 months. On DSA, the occluded segment is from C1 (B) to C7 (A). On VWI, 3D T1-weighted turbo spin-echo sequences show that the occluded segment was C2 (arrow) to C4 (arrow), and C1 did not have total occlusion (arrowheads, C). The signal intensity of distal segment is isointensity in a elliptical region-of-interest (ROI) (D). The origin segment showed a tiny lumen (arrowhead), in a circular ROI which was considered an occluded segment on DSA (E).
Tables
Asymptomatic (n = 9) Symptomatic (n = 35) P Value Male (No.) (%) 8 (88.9) 34 (97.1) .37 Age (mean) (yr) 59 (SD, 13.35) 60.51 (SD, 11.46) .73 Body mass index (mean) 25.30 (SD, 3.49) 24.40 (SD, 3.12) .46 Hypertension (No.) (%) 7 (77.8) 26 (74.3) >.99 Diabetes mellitus (No.) (%) 3 (33.3) 12 (34.3) >.99 Hyperlipidemia (No.) (%) 7 (77.8) 28 (80.0) >.99 Coronary artery disease (No.) (%) 1 (11.1) 3 (8.6) >.99 Smoker (No.) (%) 4 (44.4) 15 (42.9) >.99 Antithrombotic treatment before diagnosis of CCAO (No.) (%) 1 (11.1) 8 (22.9) .75 Antithrombotic treatment after diagnosis of CCAO (No.) (%) 3 (33.3) 18 (51.4) .55 History of radiation (No.) (%) 0 (0.0) 1 (2.9) >.99 Time intervals between DSA and VWI (median) (IQR) (days) 1 (1, 2.5) 2 (1, 4) .74 Note:—IQR indicates interquartile range.
- Table 2:
Difference in signal intensity at the origin segment of symptomatic CCAO at different stages
Hyperintensity (n = 0) Isointensity (n = 7) Hypointensity (n = 0) Heterogeneous Intensity (n = 27) P Value <7 days (No.) (%) 0 (0.0) 0 (0.0) 0 (0.0) 5 (14.7) .69 7–30 days (No.) (%) 0 (0.0) 4 (57.1) 0 (0.0) 16 (47.1) 30–90 days (No.) (%) 0 (0.0) 2 (28.6) 0 (0.0) 10 (29.4) ≥90 days (No.) (%) 0 (0.0) 1 (14.3) 0 (0.0) 3 (8.8) - Table 3:
Difference in signal intensity at the distal segment of symptomatic CCAO at different stages
Hyperintensity(n = 9) Isointensity (n = 14) Hypointensity (n = 0) Heterogeneous Intensity (n = 12) P Value <7 days (No.) (%) 2 (22.2) 1 (7.1) 0 (0.0) 2 (16.7) .29 7–30 days (No.) (%) 2 (22.2) 6 (42.9) 0 (0.0) 8 (67.7) 30–90 days (No.) (%) 4 (44.4) 4 (28.6) 0 (0.0) 2 (16.7) ≥90 days (No.) (%) 1 (11.1) 3 (21.4) 0 (0.0) 0 (0.0)
